Wockhardt Moat Analysis: Score & Risks
Wockhardt Ltd.
A first-pass moat teardown of Wockhardt Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.
Wockhardt Ltd. scores 5.21 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Cycle time optimisation resulted in increase of plant capacity by 22% (from 22 batches/month to 27 batches /month). 2. Average effective process yield improvement by 6% 3. Reduced the primary packing material consumption by 33%.”
“Today, we have a rich Intellectual Property (IP) base of 3,239 cumulative patents filed and 810 patents granted, as on 31st March, 2023.”
“5th largest (by volume & by value) generic supplier in Retail (6% volume, 6% value) and in Hospital channel (16% volume, 8% value) respectively, in Ireland”
“Tiered access centric pricing across public ↔private delivery chains to drive stewardship”
“Advancing to E. coli platform for Human Insulin, unlike most peers, helps capacity to be scaled up”
“we have received £10 million as a contribution for reserving manufacturing facility for 150 million doses per year of vaccine for 15 years. This is 150 million doses per year for about 15 year agreement.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion